微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 57.29% | 23.33% | -1.87% | 62/159 | 22.55% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 58.39% | 24.77% | 1.94% | 57/159 | 32.98% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 57.28% | 16.79% | 22.93% | 56/159 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.59% | 0.91% | 0.3% | 88/159 | 51.24% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 46.45% | -7.63% | -0.73% | 90/159 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 46.79% | -11.3% | -4.58% | 89/159 | 38.41% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 49.04% | -11.73% | 6.21% | 79/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 46.17% | -1.63% | -8.2% | 90/159 | 53.42% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 50.29% | 1.06% | -4.67% | 80/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 52.76% | 8.79% | -5.04% | 75/159 | 21.44% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 55.56% | -12.45% | 18.37% | 70/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 46.93% | 1.04% | -5.69% | 89/159 | 54.97% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 49.76% | 21.23% | 2.61% | 76/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 48.5% | 18.46% | -23.58% | 83/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 63.46% | 63.12% | 36.61% | 42/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 46.45% | 12.66% | 13.16% | 89/159 | -144.56% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 41.05% | 1.48% | 0.27% | 89/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 40.94% | -8.55% | 5.24% | 96/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 38.9% | -8.81% | -5.66% | 84/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 41.23% | 1.87% | 1.94% | 96/159 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 40.45% | -5.65% | -9.64% | 76/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 44.77% | 2.3% | 4.94% | 72/159 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 42.66% | -10.55% | 5.39% | 70/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 40.48% | 32.33% | -5.58% | 94/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 42.87% | 49.31% | -2.03% | 69/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 43.76% | 69.25% | -8.25% | 67/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 47.69% | 81.86% | 55.92% | 60/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.59% | 27.63% | 6.53% | 101/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 28.71% | 17.74% | 11.05% | 81/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 25.85% | 7.45% | -1.41% | 90/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.22% | 19.35% | 9.42% | 74/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 23.97% | 0.01% | -1.72% | 103/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 24.39% | 2.83% | 1.35% | 71/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 24.06% | 3.31% | 9.51% | 80/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 21.97% | 13.46% | -8.31% | 70/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 23.97% | 15.86% | 1.05% | 91/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 23.72% | 11.57% | 1.82% | 66/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 23.29% | 15.11% | 20.27% | 71/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 19.37% | 8.28% | -6.37% | 66/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |
| 2014-12-31 | 20.68% | 10.84% | -2.69% | 88/159 | 43.42% | 舒泰神 | 94.16% | 行业排名> |
| 2014-09-30 | 21.26% | 16% | 5.05% | 57/159 | 42.01% | 舒泰神 | 94.49% | 行业排名> |
| 2014-06-30 | 20.23% | 22.37% | 13.13% | 59/159 | 41.2% | 贝达药业 | 96.53% | 行业排名> |
| 2014-03-31 | 17.88% | 13.82% | -4.16% | 61/159 | 40.59% | 舒泰神 | 94.32% | 行业排名> |